Stage IVB Lung Cancer AJCC v8 Recruiting Phase 1 / 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0111251 (Stage IVB Lung Cancer AJCC v8)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03581487Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerTreatment